{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Symbiox Investment & Trading Co Ltd
Why is Symbiox Investme falling/rising?
On 03-Dec, Symbiox Investment & Trading Co Ltd witnessed a notable decline in its share price, closing at ₹2.66, down ₹0.14 or 5.0% from the previous session. This drop reflects a continuation of the stock’s underperformance relative to broader market benchmarks and sector peers.
Symbiox Investment & Trading Co Faces Intense Selling Pressure Amid Prolonged Downtrend
Symbiox Investment & Trading Co Ltd is currently experiencing severe selling pressure, with the stock hitting a lower circuit and an absence of buyers in the market. This extreme selling activity signals distress among investors, as the stock continues to underperform both its sector and the broader market indices.
Symbiox Investment & Trading Co Experiences Unprecedented Buying Interest Amidst Market Challenges
Symbiox Investment & Trading Co Ltd has attracted extraordinary buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This rare market phenomenon highlights a strong demand for the stock despite recent underperformance relative to broader indices and its sector peers.
Symbiox Investment & Trading Co Sees Unprecedented Buying Interest Amid Upper Circuit
Symbiox Investment & Trading Co Ltd has witnessed extraordinary buying momentum today, with the stock hitting the upper circuit and an exclusive queue of buy orders dominating the market. This rare scenario, marked by an absence of sellers, signals a potential multi-day circuit phenomenon that has captured investor attention in the Non Banking Financial Company (NBFC) sector.
Symbiox Investment & Trading Co Faces Intense Selling Pressure Amid Consecutive Losses
Symbiox Investment & Trading Co Ltd is currently experiencing severe selling pressure, with the stock registering consecutive declines and no visible buying interest. The Non Banking Financial Company (NBFC) has seen its shares fall sharply over multiple time frames, signalling distress selling and a challenging market environment for investors.
Symbiox Investment & Trading Co Faces Intense Selling Pressure Amid Market Downturn
Symbiox Investment & Trading Co Ltd, a player in the Non Banking Financial Company (NBFC) sector, is currently experiencing severe selling pressure, with only sell orders present in the market queue. This unusual trading pattern signals distress selling and highlights the challenges the stock faces amid broader market fluctuations.
Symbiox Investment & Trading Co Ltd Faces Significant Selling Pressure with 1.67% Decline Today
Symbiox Investment & Trading Co Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has declined significantly over various time frames, contrasting with the performance of the Sensex. Factors such as market sentiment and operational challenges in the NBFC sector may be influencing this downturn.
Is Symbiox Investme overvalued or undervalued?
As of November 13, 2025, Symbiox Investme's valuation has shifted from attractive to risky, indicating it is overvalued with a PE ratio of -938.62, negative ROE of -0.03%, and poor long-term performance, contrasting sharply with more stable peers like Bajaj Finance and Life Insurance.
Symbiox Investment & Trading Co Ltd Faces 5% Decline Amid Significant Selling Pressure Today
Symbiox Investment & Trading Co Ltd is experiencing significant selling pressure, with a notable decline today amid a contrasting performance from the Sensex. The stock has faced consecutive losses, underperforming both weekly and yearly benchmarks, reflecting broader market trends and sector-specific concerns.
Is Symbiox Investme overvalued or undervalued?
As of November 12, 2025, Symbiox Investme is considered an attractive investment due to its undervalued status, indicated by a high PE ratio of 36.10 and a low PEG ratio of 0.23, despite recent stock performance lagging behind the Sensex.
How has been the historical performance of Symbiox Investme?
Symbiox Investme's historical performance from March 2014 to March 2015 showed increased net sales and operating income, but profitability declined, resulting in a loss after tax and reduced margins. Despite improved cash flow and asset growth, the company faced challenges in maintaining profitability.
Symbiox Investment & Trading Co Ltd Faces Selling Pressure with 1.64% Decline Amid Year-to-Date Losses
Symbiox Investment & Trading Co Ltd is experiencing notable selling pressure, marked by consecutive losses and underperformance compared to the Sensex. Over the past year, the stock has declined significantly, reflecting a troubling trend amid broader market dynamics and company-specific challenges, despite a positive five-year performance.
Is Symbiox Investme overvalued or undervalued?
As of November 10, 2025, Symbiox Investme is fairly valued with a PE ratio of 35.02 and is more favorably positioned compared to peers like Bajaj Finance and Life Insurance, despite a year-to-date stock performance lagging at -46.31% against the Sensex's 6.91%.
Symbiox Investment & Trading Co Ltd Faces Selling Pressure with 1.97% Decline Amid Year-to-Date Losses
Symbiox Investment & Trading Co Ltd is experiencing notable selling pressure, with consecutive days of losses. The stock's year-to-date performance has declined significantly, contrasting with the Sensex's gains. Over three years, it has dropped substantially, raising concerns about its market position amid broader trends and investor sentiment.
Is Symbiox Investme overvalued or undervalued?
As of November 7, 2025, Symbiox Investme is considered overvalued with a PE ratio of 36.70 and negative EV to EBIT, despite recent short-term stock outperformance, as it significantly lags behind peers and has underperformed year-to-date and over three years.
Is Symbiox Investme overvalued or undervalued?
As of November 7, 2025, Symbiox Investme is considered overvalued with a PE ratio of 36.70, a low PEG ratio of 0.23, and a significant year-to-date decline of 43.73%, contrasting sharply with its peers and indicating weak fundamentals.
Is Symbiox Investme overvalued or undervalued?
As of November 7, 2025, Symbiox Investme is considered overvalued with a PE ratio of 36.70, contrasting sharply with its peers, and despite a recent weekly return of 2.35%, it has a year-to-date return of -43.73%, indicating significant challenges in investor confidence.
When is the next results date for Symbiox Investme?
Symbiox Investme will declare its results on 12 November 2025.
Symbiox Investment & Trading Co Ltd Gains 0.34% Today, Outperforming Sensex Amid Strong Buying Activity
Symbiox Investment & Trading Co Ltd, a microcap in the NBFC sector, is experiencing increased buying activity today, contrasting with a decline in the Sensex. While the stock has faced challenges year-to-date, it has shown significant growth over the past five years, outperforming the Sensex.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
